1. Scrip

Interview: Akari's Coversin Ticking Along Nicely

Phase II Trial Shows Promise For Rare Skin Disorder

 
• By Kevin Grogan

The C5 complement inhibitor class is in the news following UCB's bid for Ra Pharmaceuticals. Akari's CEO tells Scrip he thinks Coversin, which inhibits leukotriene B4 as well as C5, may offer more benefits in certain orphan diseases.

Ticks
Coversin is derived from a protein discovered in the saliva of the Ornithodoros moubata tick • Source: Akari Therapeutics

Akari Therapeutics PLC has presented promising data on its lead drug candidate Coversin which the UK company hopes could be a first-in-class treatment for the rare skin-blistering disorder, bullous pemphigoid (BP).

Data from an ongoing Phase II trial, presented at the European Academy of Dermatology and Venereology congress in Madrid, evaluated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.